Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Liquid biopsy reliably detects early-stage lung cancer recurrence risk (opens in a new tab)

news-medical.net · 2026-10-20

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 5Not checkedA novel study found that a blood test (liquid biopsy) can reliably detect lingering lung cancer traces in the earliest clinical stages, long before a tumor is large enough to show up on a scan.View evidenceHide evidence

As statedreliably; long before scans

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 5Not checkedThe article says the test accurately predicts relapse risk and could open a window for timely, personalized therapeutic interventions.View evidenceHide evidence

As statedaccurately predicts relapse risk

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 5Not checkedIn the study, patients with lung cancer were monitored with serial blood draws to track circulating tumor DNA (ctDNA) levels across treatment stages and compare liquid biopsy with standard imaging.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 5Not checkedThe most significant finding was that a positive tumor-DNA test served as a highly sensitive biomarker for minimal residual disease, detecting microscopic recurrence months before scans, while a negative test strongly correlated with sustained remission.View evidenceHide evidence

As statedmonths before scans

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 5Not checkedThe article says these findings could help identify high- or low-risk patients earlier, guide targeted treatment, and potentially spare some patients from overtreatment and toxicity.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

Value and research advances of ctDNA in perioperative therapy for non-small cell lung cancer.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Research Progress of Circulating Tumor DNA for Monitoring Minimal Residual Disease in Non-Small Cell Lung Cancer

2024 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.